



TB Times

Mayo Clinic Center for Tuberculosis (MCCT)

UPCOMING EVENTS

Select links for
details

[Bi-State
Infectious
Disease
Conference
2025](#)

October 3
St. Louis, MO

[TB Clinical
Intensive](#)

October 8-9
Rochester, MN
& Livestream

[Tuberculosis
\(TB\) and
Diabetes](#)

October 16
Webinar

[Civil Surgeons
Series](#)

**Inside the TB
Technical
Instructions**

November 6
Webinar

[2026 End TB
Conference of
the Union -
North America
Region](#)

Feb 26 – Mar 1
Phila, PA



Celebrating Wave 2 of TB Champions!

The Mayo Clinic Center for Tuberculosis and Stop TB USA proudly recognize the second wave of [TB Champions](#)—an inspiring group of healthcare professionals committed to advancing TB care and prevention in their communities.

This cohort includes participants throughout our region who engaged in interactive learning, deepened their TB expertise, and built strong connections with peers and mentors. Through ongoing engagement and collaboration, these Champions will continue to serve as trusted resources and advocates for TB awareness and elimination.

We applaud their dedication and welcome them to the growing TB Champions Network!

More cohorts are coming in 2026! We're excited to expand the TB Champions Network—stay tuned and [apply here](#) to get involved.

Bi-State Infectious Disease Conference 2025

Join healthcare professionals on October 3 from Missouri and Illinois for a one-day, in-person event focused on infectious disease detection, prevention, and response.

Topics Include

- Surveillance updates
- Vaccine-preventable diseases
- Antibiotic stewardship
- Emergency response strategies

Strengthen your practice and public health impact—[register](#) by September 26!

Don't forget! TB Clinical Intensive October 8-9!

Join the [TB Clinical Intensive 2025](#) at Mayo Clinic in Rochester, MN – October 8–9, 2025!



Don't miss this two-day learning experience designed for clinicians and public health professionals working in TB care and prevention. The **TB Clinical Intensive 2025** offers expert-led sessions on the latest in **diagnosis, treatment, and prevention strategies**, with practical tools to support care across disciplines.


Attend in person or via livestream to gain practical insights that improve clinical decisions and advance TB care.

[Reserve your spot today!](#)

JCTUBE Spotlight

[Symptomatic \(STB\) and Asymptomatic \(ATB\) Tuberculosis in Italy: Results from a Multicenter Retrospective Study](#)

A multicenter study from Italy found that 36% of pulmonary TB cases were asymptomatic, making them harder to detect and potentially contributing to ongoing transmission. While symptomatic TB (STB) was linked to more adverse events and longer hospital stays, treatment outcomes were similar between symptomatic and asymptomatic cases.




These findings highlight the need for improved screening and awareness of asymptomatic TB (ATB) in global elimination efforts.

[The World Health Organization's 2024 report](#) on asymptomatic TB offers further insights into its epidemiology, detection challenges, and implications for public health.

TB Research News

[Facing Drug Resistance in TB: Insights from the endTB-Q Trial](#)

A Phase 3 trial published in [The Lancet Respiratory Medicine](#) evaluated a shortened, all-oral regimen—bedaquiline, delamanid, linezolid, and clofazimine (BDLC)—for treating pre-extensively drug-resistant tuberculosis (pre-XDR TB). Conducted across six countries, the study enrolled 324 patients and compared BDLC (6–9 months) to the WHO-recommended standard (18–24 months).




The BDLC regimen showed similar treatment success in patients with limited disease, especially with the 6-month version, which achieved a 93% success rate. However, non-inferiority was not demonstrated overall, particularly in patients with extensive disease. Adverse events were common in both groups, with slightly higher rates in the BDLC arm.

These findings suggest BDLC may be a viable option for select patients but highlight the need for longer or reinforced treatment in more severe cases. The results support a personalized approach to drug-resistant TB care and underscore the importance of further research.

[Mining the CD4 Antigen Repertoire for Next-generation Tuberculosis Vaccines](#)

Researchers have developed a trivalent mRNA-based TB vaccine that shows stronger protection than the current BCG vaccine in mouse models. The vaccine targets three CD4 T cell antigens—PPE20, EsxG, and PE18—identified through an efficacy screen. These antigens demonstrated immunologic cross-reactivity and triggered immune responses in 84% of humans exposed to *M. tuberculosis*. Delivered via lipid nanoparticles, the vaccine represents a promising step toward more effective TB prevention. The study was published in [Cell](#) on September 15, 2025.



Newsletter Content Suggestions

We invite you to be active participants in shaping the content of our newsletter. We will do our best to provide clarity on your TB related questions and include topics and events you would like to showcase. Simply submit your ideas to [TB Times Content Suggestion](#). Each issue we will feature suggested content, making this newsletter a true reflection of your needs.

Vision

To become a regionally, nationally, and internationally recognized Center of Excellence for tuberculosis.

Mission

To contribute, in a meaningful way, to the control, management, and elimination of tuberculosis regionally, nationally, and globally.



Medical Consultation

MCCT provides expert medical consultation to public health and medical professionals in our assigned region. We have colleagues with expertise in public health nursing, pharmacy, laboratory, occupational health, pediatrics, and radiology just to name a few.

Consultations can be requested using one of the following options:

- Submit at [IDCrowd Platform](#)
- Email tbcenter@mayo.edu
- Call 507-284-0275

IDCrowd is the preferred platform for submitting requests used by all TB COEs. If you are using IDCrowd for the first time, choose the option to register for a new membership. Additional information on how to submit a request can be found [here](#).

Mini Fellowships

As part of the TB COE initiatives, MCCT is providing mini-fellowship opportunities for healthcare professionals seeking to deepen their understanding of TB.

Experiences will be curated to meet individual learning needs. Some experiences that may be offered include shadowing healthcare professionals as they interact with patients, observing directly observed therapy (DOT), and participating in TB case reviews.

You can find out more information by emailing tbcenter@mayo.edu. To be considered for a mini fellowship, please submit an [application here](#).

Educational Requests

MCCT is able to support a variety of TB related needs including virtual and in-person training, educational material development, and technical assistance. Please contact us to discuss ways we can support your work in treating and preventing tuberculosis.

Contact Us



Tbcenter@mayo.edu



centerfortuberculosis.mayo.edu



507-284-0275